Canton Strategic Holdings (CNTN) Share-based Compensation (2021 - 2026)
Canton Strategic Holdings (CNTN) posted Share-based Compensation of $32.3 million for Q1 2026, up 1951.78% on a QoQ basis from $1.6 million in Q4 2025, and up 14618.45% year-over-year from N/an in Q1 2025.
Canton Strategic Holdings (CNTN) Share-based Compensation (2021 - 2026) Analysis & Trends
Canton Strategic Holdings' Share-based Compensation history runs 6 years deep, the most recent figure standing at $32.3 million for Q1 2026.
- Quarterly Share-based Compensation rose 14618.45% year-over-year to $32.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $34.6 million (up 4358.39% YoY) and the FY2025 annual result came in at $2.9 million, up 305.15% from the prior year.
- Share-based Compensation was $32.3 million for Q1 2026 at Canton Strategic Holdings, up from $1.6 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $32.3 million in Q1 2026 and bottomed at $19381.0 in Q1 2022.
- A 5-year average of $2.2 million and a median of $202002.0 in 2022 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2022 — Share-based Compensation slumped 97.12% — and 2026, when it surged 14618.45%.
- Canton Strategic Holdings' Share-based Compensation stood at $202002.0 in 2022, then sank by 50.5% to $100000.0 in 2023, then soared by 111.1% to $211104.0 in 2024, then soared by 644.79% to $1.6 million in 2025, then jumped by 1951.78% to $32.3 million in 2026.
- Business Quant data shows CNTN's Share-based Compensation at $32.3 million in Q1 2026, $1.6 million in Q4 2025, and $200000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 6.39 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 9.26 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 1.18 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 166.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 257.40 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 87.30 Mn |
| 10 | Canton Strategic Holdings | 427.87 Mn | 427.87 Mn | - | 32.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 32.26 Mn |
| Mar 31, 2026 | 32.26 Mn |
| Dec 31, 2025 | 1.57 Mn |
| Dec 31, 2025 | 1.57 Mn |
| Sep 30, 2025 | 200,000.00 |
| Sep 30, 2025 | 200,000.00 |
| Jun 30, 2025 | 559,383.00 |
| Jun 30, 2025 | 559,383.00 |
| Mar 31, 2025 | 219,179.00 |
| Mar 31, 2025 | 219,179.00 |
| Dec 31, 2024 | 211,104.00 |
| Dec 31, 2024 | 211,104.00 |
| Sep 30, 2024 | 191,943.00 |
| Sep 30, 2024 | 191,943.00 |
| Jun 30, 2024 | 153,647.00 |
| Jun 30, 2024 | 153,647.00 |
| Mar 31, 2024 | 153,619.00 |
| Mar 31, 2024 | 153,619.00 |
| Dec 31, 2023 | 100,000.00 |
| Dec 31, 2023 | 100,000.00 |